From: In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
Characteristics | n = 131 |
---|---|
Age (yrs) | 55 (48–62) |
Gender | |
Female (%) | 24 (18.32%) |
Male (%) | 107 (81.68%) |
HBeAg | |
Positive(%) | 26 (19.74%) |
Negative(%) | 77 (58.77%) |
Not available(%) | 28 (21.37%) |
Serum HBsAga (IU/mL) | |
<250 | 35 (33.98%) |
>250 | 68 (66.02%) |
Serum HBV DNAb (IU/mL) | |
<500 | 78 (68.42%) |
>500 | 36 (31.58%) |
Diagnostic markers | |
Ki-67 | 131 (100%) |
Hep-par1 | 127 (96.95%) |
GPC-3 | 128 (97.71%) |
GSc | 125 (96.15%) |
HSP70d | 124 (96.88%) |
α-fetoprotein (ng/ml) | 39.9 (8.0–522.2) |
Alanine transferase ALT (U/L) | 31.0 (21.0–49.3) |
Necro-Inflammation (G1,G2,G3,NA) | 17:66:30:18 |
Fibrosis (S1,S2,S3,S4,NA) | 5:6:4:98:18 |
Tumor Differentiation (1,2,3) | 12:98:21 |
MVI (M0,M1,M2) | 60: 44: 27 |
Satellite nodule | 7 (5.34%) |
Nodule in nodule | 27 (20.61%) |
Recurrence | |
Yes | 68 (51.90%) |
No | 61 (46.56%) |
death | 2 (1.52%) |